Nifty Smallcap 100 Plunges to 14,986 Low: Why Mid- and Small-Caps Are Crashing Harder Than the Market in March 2026

  The Indian stock market witnessed intense selling pressure on March 23, 2026, as mid- and small-cap indices tumbled over 4% amid a broader market crash driven by escalating geopolitical tensions in the Middle East. The Nifty Midcap 100 index has now declined around 13% year-to-date in 2026, reflecting sharp corrections in broader market segments that have outperformed in previous years but are now facing heightened volatility. Sharp Intraday Declines in Midcap and Smallcap Indices The Nifty Smallcap 100 index opened at 15,565.30 on Monday but quickly slipped to an intraday low of 14,986, erasing significant ground in early trade. By the afternoon session, the selling intensified, with the index down over 4% at points during the day. Market breadth was overwhelmingly negative—except for isolated performers like Trident (up around 2.85%), virtually every stock in the Nifty Smallcap 100 traded in the red, signaling widespread panic across smaller companies. Similarly, the Nifty M...
0

The Promising Future of India’s Pharmaceutical Sector: A Spotlight on Key Players


 India is poised for a remarkable transformation in its pharmaceutical sector, with projections indicating a market value of $130 billion by 2030. According to a recent report released by Deloitte during the Assocham Annual Pharma Summit, India, currently the world’s third-largest drug producer by volume, is making significant strides on the global stage.

India’s Growing Influence in Global Pharmaceuticals

As a key player in the global pharmaceutical arena, India exports products to over 200 countries, solidifying its reputation as a leading manufacturer of generic drugs. However, the report emphasizes a pivotal shift: India is transitioning from a focus on generics to becoming a powerhouse of pharmaceutical innovation. This evolution is supported by advancements in research, regulatory reforms, and strategic partnerships on a global scale.

Key Players in the Indian Pharmaceutical Sector

Granules India Ltd

Overview

Granules India Ltd is primarily engaged in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages. With a market capitalization of ₹13,478 crore, the company is positioned as a key player in the pharmaceutical manufacturing sector.

Financials

  • Current Price: ₹556
  • High / Low: ₹725 / ₹319
  • P/E Ratio: (not provided in detail)

Granules India is focused on providing high-quality, cost-effective solutions, ensuring compliance with international standards, and catering to a diverse clientele across the globe.

Glenmark Pharmaceuticals Ltd

Overview

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with a presence across generics, specialty, and OTC (over-the-counter) markets. With operations in over 80 countries, Glenmark has built a reputation for innovation and quality.

Financials

  • Market Cap: ₹47,568 crore
  • Current Price: ₹1,686
  • High / Low: ₹1,774 / ₹702
  • Book Value: ₹278
  • Dividend Yield: 0.15%
  • P/E Ratio: 27.4

Glenmark's strategic focus on research and development enables it to remain competitive and responsive to market needs, contributing to its robust growth.

Gufic Biosciences Ltd

Overview

Gufic Biosciences Ltd specializes in the manufacture of pharmaceuticals, medicinal chemicals, and botanical products. The company is known for its commitment to quality and innovation, making significant strides in various therapeutic areas.

Financials

  • Market Cap: ₹3,815 crore
  • Current Price: ₹380
  • High / Low: ₹435 / ₹237
  • Book Value: ₹53.1
  • Dividend Yield: 0.03%
  • P/E Ratio: 44.2

With a strong focus on research and development, Gufic Biosciences is well-positioned to expand its product offerings and market reach.

Gujarat Themis Biosyn Ltd

Overview

Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients through a fermentation process. The company has established itself as a reliable player in the pharmaceutical manufacturing sector.

Financials

  • Market Cap: ₹4,016 crore
  • Current Price: ₹369
  • High / Low: ₹390 / ₹108
  • Book Value: ₹18.5
  • Dividend Yield: 0.18%
  • P/E Ratio: 73.4

Gujarat Themis Biosyn's emphasis on fermentation technology and commitment to quality positions it as a leader in sustainable pharmaceutical production.

Conclusion

The Indian pharmaceutical sector is on the verge of significant growth, driven by innovative companies like Granules India, Glenmark Pharmaceuticals, Gufic Biosciences, and Gujarat Themis Biosyn. As they continue to expand their product lines and improve manufacturing processes, these firms are not only enhancing India's position in the global market but also contributing to advancements in healthcare.

Investors and stakeholders should keep an eye on these companies as they navigate the evolving landscape, presenting opportunities for growth and collaboration in the promising pharmaceutical sector.

Comments

Post a Comment